Co-diagnostics, inc. to announce expansion of oem agreement with bio molecular systems at aacc

Salt lake city , july 26, 2022 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) ("co-dx" or the "company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be disclosing the global expansion of its oem agreement with bio molecular systems (bms) at the company's customer and distributor update today at aacc. located in the gold coast area of queensland, australia, bms includes the founders and senior personnel from the company responsible for inventing and developing the original rotor-gene real-time pcr instrument, with a reputation for expertise in developing innovative, versatile, robust, and easy-to-use products.
CODX Ratings Summary
CODX Quant Ranking